Prevalent role of Akt and ERK activation in cardioprotective effect of Ca2+ channel- and beta-adrenergic receptor blockers

2008 ◽  
Vol 321 (1-2) ◽  
pp. 155-164 ◽  
Author(s):  
Krisztina Kovacs ◽  
Katalin Hanto ◽  
Zita Bognar ◽  
Antal Tapodi ◽  
Eszter Bognar ◽  
...  
Keyword(s):  
Adrenergic Receptor ◽  
Cardioprotective Effect ◽  
Beta Adrenergic Receptor ◽  
Beta Adrenergic ◽  
Erk Activation ◽  
Receptor Blockers

scholarly journals Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients

2020 ◽  
Vol 55 (5) ◽  
pp. 597-605
Author(s):  
Ruzan Udumyan ◽  
Scott Montgomery ◽  
Ann-Sofi Duberg ◽  
Fang Fang ◽  
Unnur Valdimarsdottir ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Cancer Mortality ◽  
Adrenergic Receptor ◽  
Beta Adrenergic Receptor ◽  
Beta Adrenergic ◽  
National Cohort ◽  
Receptor Blockers

Role of serotonergic input in the regulation of the beta-adrenergic receptor-coupled adenylate cyclase system

Science ◽  
1982 ◽  
Vol 218 (4575) ◽  
pp. 900-901 ◽  
Author(s):  
A Janowsky ◽  
F Okada ◽  
D. Manier ◽  
C. Applegate ◽  
F Sulser ◽  
...  
Keyword(s):  
Adenylate Cyclase ◽  
Adrenergic Receptor ◽  
Adenylate Cyclase System ◽  
Beta Adrenergic Receptor ◽  
Beta Adrenergic

scholarly journals Beta-Adrenergic Receptor Blockers and Hepatocellular Carcinoma Survival. A Systemic Review and Meta-Analysis

2021 ◽  
Author(s):  
Hyun Chang ◽  
Sung Hyun Lee
Keyword(s):  
Hepatocellular Carcinoma ◽  
Random Effects ◽  
Beta Blocker ◽  
Adrenergic Receptor ◽  
Meta Analysis ◽  
Systemic Review ◽  
Cochrane Library ◽  
Beta Adrenergic Receptor ◽  
Beta Adrenergic ◽  
Receptor Blockers

Abstract IntroductionPre-clinical data has revealed that beta-adrenergic stimulation can affect the growth and progression of different types of malignancies. Beta-adrenergic receptor blockers have been associated with improved survival in patients with many types of cancer. We performed a meta-analysis to investigate the association between beta-blocker use and hepatocellular carcinoma (HCC) prognosis.MethodsIn this meta-analysis, a full search was conducted using PubMed, the Cochrane library, and Embase to identify all relevant studies published up to May 2021. Available hazard ratios (HRs) were extracted for overall survival (OS), cancer-specific survival (CSS) and pooled using a random effects meta-analysis.ResultsFour studies involving 7252 patients with HCC met the inclusion criteria and were included in the systemic review. Three studies that reported OS data of 5148 patients were included in the meta-analysis. The random-effects model showed that beta-blocker use was associated with significantly improved OS in HCC (HR = 0.69, 95% CI = 0.54-0.88, P = 0.0031), without significant heterogeneity (I2 = 41%; Q = 6.42, P = 0.18)ConclusionThis meta-analysis suggested that beta-blocker use can be associated with prolonged OS of patients with HCC.

Sign in / Sign up

Export Citation Format

Share Document